PR Newswire Clinical TrialsOriginal article
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
Phase 3KSI-501afliberceptPositive
AI Analysis
Summary
Kodiak Sciences announced the first patient enrollment in the global Phase 3 ALTO trial evaluating KSI-501 versus aflibercept in diabetic macular edema patients. The trial is designed to demonstrate the superiority of KSI-501 over the comparator drug.
Clinical Trial Data
Phase
Phase 3
Outcome Details
First patients enrolled in global Phase 3 ALTO trial
Importance:6/10
Sentiment:
0.50
Phase 3Clinical TrialDiabetic Macular EdemaRetinaKSI-501
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 10, 2026 8:43 PM